b'Peak Respiratory Severity of Adults Hospitalized With Respiratory Syncytial Virus (RSV), COVID-19, or Influenza by Vaccination StatusSource: Severity of Respiratory Syncytial Virus vs. COVID-19 and Influenza Among Hospitalized US Adults. JAMA Network Open. 2024;7(4):e244954. doi:10.1001/jamanetworkopen.2024.4954In adjusted analyses, the odds of IMV or in-hos- The study concluded that, among adults hospital-pital death were not significantly different amongized in this U.S. cohort during the 16 months before patientshospitalizedwithRSVandunvaccinatedthe first RSV vaccine recommendations, RSV dis-patientshospitalizedwithCOVID-19(adjustedease was less common but similar in severity com-odds ratio [aOR], 0.82; 95% CI, 0.59-1.13; P = .22)pared with COVID-19 or influenza disease among or influenza (aOR, 1.20; 95% CI, 0.82-1.76; P = .35);unvaccinated patients and more severe than COVID-however, the odds of IMV or death were signifi- 19 or influenza disease among vaccinated patients for cantly higher among patients hospitalized with RSVthe most serious outcomes of IMV or death.compared with vaccinated patients hospitalized with1Surie D, Yuengling KA, DeCuir J, et al. Severity of Respiratory COVID-19 (aOR, 1.38; 95% CI, 1.02-1.86; P = .03)Syncytial Virus vs COVID-19 and Influenza Among Hospitalized or influenza disease (aOR, 2.81; 95% CI, 1.62-4.86;US Adults. JAMA Network Open. 2024;7(4):e244954. doi:10.1001/P .001), the authors wrote. jamanetworkopen.2024.49547'